Cite
HARVARD Citation
Brown, J. et al. (2023). Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet oncology. 24 (3), pp. 213-227. [Online].